Tango Therapeutics, Inc. (TNGX) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative biotech momentum setup: shares have broken out ~31% over 21 days (12.5→16.45) above prior consolidation, supported by fresh analyst coverage (Moderate Buy), new institutional buying and upcoming JPMorgan presentation. With resistance near ~17 and strong recent ROC, any positive clinical or corporate update could fuel a further momentum spike in the short term, though cash burn and lack of near-term data keep risk high.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • Heavy cash burn • Low efficiency TNGX has a strong balance sheet and liquidity position, but its heavy losses, negative free cash flow, and weak operating efficiency continue to pressure the investment case.
Price Behavior
Key Price Behavior Insights: • Strong uptrend • Failed breakout • Hold support Support Level: $25.0–$25.8 Resistance Level: $27.77 TNGX has been in a strong uptrend over the last month, but after a sharp push to $27.77 it has pulled back and now needs to hold the $25.0–$25.8 support zone to keep the bullish setup intact.
Sentiment & News
Key News Insights: • Institutional Buying • Insider Sales • Leadership Update Tango Therapeutics is seeing fresh institutional buying and leadership reinforcement even as repeated insider sales by Adam Crystal weigh on sentiment amid late-stage pipeline progress.
AI Summary
TNGX has shifted from a speculative biotech to a credible late-stage execution story, but the stock's rerating now leaves investors exposed to binary clinical/regulatory disappointment, so the key takeaway is to watch whether upcoming pipeline milestones can validate the higher valuation before cash burn and dilution risk start to matter more.
Description
Tango Therapeutics is a Cambridge, Massachusetts–based biotechnology company that discovers and develops small-molecule therapies for cancer. Its lead candidate, TNG908, is a PRMT5 inhibitor targeting tumors with MTAP deletions, and the pipeline includes inhibitors directed at USP1 for BRCA1/2-mutant cancers and a program for STK11-mutant tumors. The company maintains a strategic discovery and development collaboration with Gilead Sciences and was founded in 2017.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | TNGX | Tango Therapeutics, Inc. | Speculative biotech momentum setup: shares have broken out ~31% over 21 days (12.5→16.45) above prior consolidation, supported by fresh analyst coverage (Moderate Buy), new institutional buying and upcoming JPMorgan presentation. With resistance near ~17 and strong recent ROC, any positive clinical or corporate update could fuel a further momentum spike in the short term, though cash burn and lack of near-term data keep risk high. | Closed | +13.2% |